The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 26, 2024

Filed:

Dec. 01, 2020
Applicants:

Innovative Cellular Therapeutics Holdings, Ltd., George Town, KY;

Innovative Cellular Therapeutics, Inc., Rockville, MD (US);

Inventors:

Lei Xiao, Rockville, MD (US);

Zhiyuan Cao, Shanghai, CN;

Chengfei Pu, Shanghai, CN;

He Sun, Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 14/82 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 38/191 (2013.01); A61K 38/204 (2013.01); A61K 38/208 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/82 (2013.01); C07K 16/2818 (2013.01); C12N 15/86 (2013.01);
Abstract

The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.


Find Patent Forward Citations

Loading…